NCT06845163View on ClinicalTrials.gov

Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema

PHASE2RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 8, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

August 31, 2026

Conditions
Diabetic Macular EdemaCenter-involved Diabetic Macular Edema
Interventions
DRUG

Dapagliflozin

Dapagliflozin 10 mg will be given orally once daily for three months.

DRUG

Anti-VEGF drug

Aflibercept 2 mg (0.05 ml) will be administered by intravitreal injection every month for three consecutive months.

Trial Locations (1)

Unknown

RECRUITING

Alexandria Main University Hospital, The Ophthalmology Department, Faculty of Medicine, Alexandria University, Alexandria

All Listed Sponsors
lead

Alexandria University

OTHER